JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M004005200 on July 25, 2000

J. Biol. Chem., Vol. 275, Issue 41, 31594-31600, October 13, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/41/31594    most recent
M004005200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, X.
Right arrow Articles by Wang, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, X.
Right arrow Articles by Wang, P. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Changing the Donor Cofactor of Bovine alpha 1,3-Galactosyltransferase by Fusion with UDP-galactose 4-Epimerase

MORE EFFICIENT BIOCATALYSIS FOR SYNTHESIS OF alpha -Gal EPITOPES*

Xi Chen, Ziye Liu, Jianqiang Wang, Jianwen Fang, Hongni Fan, and Peng George WangDagger

From the Department of Chemistry, Wayne State University, Detroit, Michigan 48202

Received for publication, May 10, 2000, and in revised form, July 14, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Two fusion enzymes consisting of uridine diphosphogalactose 4-epimerase (UDP-galactose 4-epimerase, EC 5.1.3.2) and alpha 1,3-galactosyltransferase (EC 2.4.1.151) with an N-terminal His6 tag and an intervening three-glycine linker were constructed by in-frame fusion of the Escherichia coli galE gene either to the 3' terminus (f1) or to the 5' terminus (f2) of a truncated bovine alpha 1,3-galactosyltransferase gene, respectively. Both fusion proteins were expressed in cell lysate as active, soluble forms as well as in inclusion bodies as improperly folded proteins. Both f1 and f2 were determined to be homodimers, based on a single band observed at about 67 kDa in SDS-polyacrylamide gel electrophoresis and on a single peak with a molecular mass around 140 kDa determined by gel filtration chromatography for each of the enzymes. Without altering the acceptor specificity of the transferase, the fusion with the epimerase changed the donor requirement of alpha 1,3-galactosyltransferase from UDP-galactose to UDP-glucose and decreased the cost for the synthesis of biomedically important Galalpha 1,3Gal-terminated oligosaccharides by more than 40-fold. For enzymatic synthesis of Galalpha 1,3Galbeta 1,4Glc from UDP-glucose and lactose, the genetically fused enzymes f1 and f2 exhibited kinetic advantages with overall reaction rates that were 300 and 50%, respectively, higher than that of the system containing equal amounts of epimerase and galactosyltransferase. These results indicated that the active sites of the epimerase and the transferase in fusion enzymes were in proximity. The kinetic parameters suggested a random mechanism for the substrate binding of the alpha 1,3-galactosyltransferase. This work demonstrated a general approach that fusion of a glycosyltransferase with an epimerase can change the required but expensive sugar nucleotide to a less expensive one.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Oligosaccharides are attractive targets for the development of new pharmaceuticals because of their important roles in cell recognition, cell signaling, and other biological processes (1, 2). alpha -Gal1 epitopes (Galalpha 1,3Gal-terminated oligosaccharide sequences including di-, tri-, and pentasaccharides) have drawn increasing attention since it was discovered that the interaction of preexisting natural antibodies in human serum with this specific xenoactive oligosaccharide sequence on animal cells is the main cause of hyperacute rejection in xenotransplantation (3). alpha -Gal epitopes exist as glycolipids or glycoproteins on the cell surface of mammals other than humans, apes, and Old World Monkeys (4, 5). The unique enzyme responsible for the formation of the terminal glycoside bond in nature is UDP-Gal:Galbeta 1,4GlcNHAc alpha 1,3-galactosyltransferase (alpha 1,3GalT), a protein that is absent in humans due to mutational inactivation of the gene (6, 7). In contrast, humans produce a large amount of anti-Gal antibodies including IgG, IgM, and IgA isotypes (8).

The discovery of the interaction of anti-Gal and alpha -Gal epitopes has led to experimental attempts to overcome hyperacute rejection by either depleting the recipient's anti-Gal through alpha -Gal-immobilized affinity columns or antagonizing anti-Gal by infusing the recipient's body with soluble synthetic alpha -Gal oligosaccharides (9, 10). However, such procedures require access to a substantial amount of alpha -Gal oligosaccharides as well as synthetically derived alpha -Gal analogs and mimetics. Due to the high cost associated with multiple protection and deprotection steps with a tedious separation procedure at each step in traditional chemical synthesis of oligosaccharides (11-13), the most practical production of alpha -Gal oligosaccharides is by glycosyltransferase-catalyzed enzymatic synthesis (14). Nevertheless, since sugar nucleotides required by glycosyltransferases are exceptionally expensive, much work has been focused on in situ sugar nucleotide regeneration through multiple-enzyme systems (15-18) and on enzymatic transformation to inexpensive sugar derivatives. We have demonstrated that a number of alpha -Gal oligosaccharides can be synthesized by glycosyltransferase-catalyzed reactions with regeneration of UDP-Gal through a five-enzyme system (19). Such a multiple-enzyme system undoubtedly increased the complexity of the reaction. We also showed that a simpler alternative was a two-enzyme system in which UDP-galactose 4-epimerase (GalE) converted relatively inexpensive sugar nucleotide UDP-Glc to UDP-Gal, and alpha 1,3-galactosyltransferase carried out the subsequent glycosylation reaction (19). In order to further reduce the cost of alpha -Gal synthesis as well as to avoid multiple fermentation for enzyme preparations, in this work two bifunctional fusion proteins containing both GalE and alpha 1,3GalT were constructed. GalE carries out the interconversion of UDP-Glc to UDP-Gal, and alpha 1,3GalT catalyzes the transfer of galactose from UDP-Gal to N-acetyllactosamine or its derivatives (Fig. 1A). The overall function of the fusion proteins is the transfer of galactose from UDP-Glc to the acceptor (Fig. 1B). These fusion enzymes change the donor requirement of the alpha 1,3GalT from UDP-Gal to UDP-Glc. Furthermore, the fused enzyme system that catalyzes a sequential reaction may also have a kinetic advantage over the mixture of two separated enzymes, since the product of one enzyme travels a shorter distance to be captured by the next enzyme (20, 21).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Reactions catalyzed by UDP-Gal 4-epimerase, alpha 1,3-galactosyltransferase, or fusion enzymes (f1, f2). A, reactions catalyzed by separated UDP-Gal 4-epimerase (catalyzing the interconversion of UDP-Glc and UDP-Gal) or alpha 1,3-galactosyltransferase (producing alpha -Gal trisaccharide from UDP-Gal and lactose). B, reaction catalyzed by f1 or f2 (producing alpha -Gal trisaccharide from UDP-Glc and lactose).

Glycosyltransferases can be classified mechanistically into two major families, inverting glycosyltransferases and retaining glycosyltransferases, depending on the anomeric configuration at the reaction center. alpha 1,3GalT belongs to the retaining family, since it transfers a galactose residue from an alpha -linked nucleotide diphospho sugar (UDP-galactose) to the acceptor, forming an alpha -linked product via the retention of the anomeric configuration. The reaction mechanism was proposed to consist of two nucleophilic substitutions at the sugar anomeric carbon including the transient formation of a glycosyl enzyme intermediate (22-24). However, the details of the catalytic mechanism of alpha 1,3GalT remain unknown due to the unavailability of the three-dimensional structure of any retaining glycosyltransferase. The comparison of the kinetic parameters of two fusion proteins with reverse sequence as well as of the native alpha 1,3GalT could provide insights into the mechanism of the alpha 1,3GalT-catalyzed reaction.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Chemicals and Reagents-- Plasmid vector pET15b was purchased from Novagen Inc., Madison, WI. Ni2+-NTA-agarose, polymerase chain reaction purification kit, QIAEX II gel extraction kit, QIAamp tissue kit, and DNA miniprep spin kit were from Qiagen (Santa Clarita, CA). All restriction enzymes, Taq DNA polymerase, 1-kb DNA ladder, and T4 DNA ligase were obtained from Promega (Madison, WI). beta -Lactose (4-O-beta -D-galactopyranosyl-beta -D-glucose), D(+)-galactosamine, melibiose (6-O-alpha -D-galactopyranosyl-D-glucose), UDP-Gal, UDP-Glc, UDP-D-[6-3H]glucose, ampicillin, ammonium sulfate, 2-mercaptoethanol, Folin and Ciocalteu's phenol reagent, and DOWEX 1 × 8 anion exchange resin were obtained from Sigma. D-Ribose and 2-hydroxyethyl disulfide were from Aldrich. Guanidine hydrochloride, sodium chloride, and ScintiVerse BD were from Fisher. Low range protein standards was from Bio-Rad. High and low molecular weight gel filtration calibration kits and UDP-D-[6-3H]galactose were from Amersham Pharmacia Biotech. All other chemicals were obtained in reagent grade from commercially available sources.

Bacterial Strains and Plasmids-- Escherichia coli strain K-12 (substrain MG1655) was from ATCC (ATCC catalog no. 47076). Plasmid vector pET15b and E. coli competent cell BL21(DE3) [F- ompT hsdSB(rB-mB-) gal dcm (DE3)] were from Novagen Inc. (Madison, WI). Plasmid pET15b-alpha 1,3GalT was constructed as described previously (19). E. coli competent cell DH5alpha (lacZDelta M15 hsdR recA) was from Life Technologies, Inc.

Construction of Plasmids pET15b-f1 and pET15b-f2-- Chromosomal DNA of E. coli strain K-12 was purified using the QIAamp tissue kit. All of the polymerase chain reactions were performed in a total 50-µl reaction volume containing 5 µl (0.2 µg) of template DNA, a 1 µM concentration of each of two corresponding primers, MgCl2 (2.5 mM), 5 µl of 10× buffer B (100 mM Tris-HCl, pH 8.3, at 25 °C, 500 mM KCl), 1 mM dNTPs, and 2.5 units of Taq polymerase. The reaction mixture was covered with 50 µl of mineral oil and subjected to 30 cycles of amplification with an annealing temperature of 55 °C in a Thermolyne Amplitron I thermal cycler (Barnstead Thermolyne Corp., Dubque, IA). Restriction digestions and DNA ligations were performed as directed by the enzyme manufacturers. The resulting plasmids were transformed into E. coli cloning strain DH5alpha and then expression strain BL21 (DE3). Selected clones were characterized by restriction mapping and DNA sequencing. The strategy for constructing plasmids for fusion enzymes is described in "Results."

Overexpression and Purification of the Fusion Enzymes-- The expression and purification of the fusion enzymes from the cell lysate were as described before (19). Briefly, the overexpression of the enzymes was induced by 0.4 mM isopropyl-1-thio-beta -D-galactopyranoside for 3 h at 37 °C in a C25 incubator shaker (New Brunswick Scientific Co., Inc., Edison, NJ). The cell lysate and inclusion bodies were separated by centrifugation at 12,000 rpm for 20 min.

From cell lysate, the active enzymes were purified using a Ni2+-NTA-agarose affinity column. After elution, the fractions containing the purified enzyme (detected by UV-visible spectrometry) were combined, and ammonium sulfate was slowly added with stirring to 80% saturation. The suspension was kept at 4 °C for an additional 30 min and then centrifuged. The pellet was dissolved in 20 mM Tris-HCl, pH 7.9, and applied to a Superdex 200 preparation FPLC column preequilibrated with Tris-HCl buffer (50 mM, pH 8.0) containing 2-mercaptoethanol (10 mM), glycerol (10%), and NaCl (0.25 M). The column was then eluted with the same buffer, and fractions containing fusion protein activity were pooled and concentrated in a Centricon 3 concentrator (Millipore Corp., Bedford, MA).

To obtain the active fusion proteins from the inclusion bodies, the purification and refolding procedures were carried out as described in Ref. 25 except that a calculated E280 nm0.1% value of 1.6 (26) was used for the fusion enzymes for the determination of enzyme concentration.

SDS-PAGE-- SDS-PAGE was performed in a 10% gel in a Mini Protein III cell gel electrophoresis unit (Bio-Rad) at DC 200 V. High range (40-212 kDa) SDS-PAGE standards (Promega) were used as molecular weight standards, and the gel was stained with Coomassie Blue.

Assay for Fusion Enzymes-- Enzyme assays for fusion proteins were performed at 37 °C for 30 min in a final volume of 100 µl containing Tris-HCl (10 mM, pH 7.0), MnCl2 (10 mM), bovine serum albumin (0.1%), UDP-D-[6-3H]galactose (0.3 mM) or UDP-D-[6-3H]glucose (final specific activity of 1000 cpm/nmol), fusion enzyme (6.3 pmol), and acceptor (50 mM, lactose or lactose derivatives). Acceptor was omitted for blank. The reaction was stopped by adding 100 µl of ice-cold EDTA (0.1 M). Dowex 1 × 8-200 chloride anion exchange resin was then added in a water suspension (0.8 ml, 1:1 (v/v)). After centrifugation, supernatant (0.5 ml) was collected in a 20-ml plastic vial, and ScintiVerse BD (5 ml) was added. The vial was vortexed thoroughly before the radioactivity of the mixture was counted in a liquid scintillation counter (Beckmann LS-3801 counter). One unit of fusion enzyme activity is defined as the amount of enzyme that catalyzes the transfer of 1 µmol of galactose from UDP-Glc to lactose/min at 37 °C.

Determination of Kinetic Parameters-- Kinetic parameters for the coupled reaction (UDP-Glc right-arrow Galalpha 1,3Lac) were gained by assays with UDP-[6-3H]Glc (0.3 mM) and varying concentrations of lactose (7, 8, 10, 12.5, 17, 25, and 50 mM) at 37 °C for 30 min, in which the formation of the product [6-3H]Galalpha 1,3Lac was measured by scintillation counting. Kinetic parameters for the alpha 1,3-galactosyltransferase moiety (UDP-Gal right-arrow Galalpha 1,3Lac reaction) in f1 or f2 were obtained by a modification of the standard assay for the transferase (19), with UDP-[6-3H]Gal (0.3 mM) and varying concentrations of lactose (7, 8, 10, 12.5, 17, 25, and 50 mM). Enzymatic activity of the epimerase moiety (UDP-Glc right-arrow UDP-Gal reaction) in the fusion enzymes was obtained with different concentrations of UDP-[6-3H]Glc (1, 1.14, 1.4, 1.6, 2, 2.6, and 4 mM) at 24 °C for 5 min. After deactivating the enzyme by heating at 100 °C for 10 min, the amount of UDP-[6-3H]Gal formed by the epimerase was quantitatively determined by using an excess amount of alpha 1,3GalT to transfer all of the UDP-[6-3H]Gal to [6-3H]Galalpha 1,3Lac. This previously established alpha 1,3GalT-coupled radioactivity assay was proven to be a convenient method for the determination of the epimerase activity (27). The concentrations of all enzymes were determined by the Lowry method (28) and adjusted to 0.3 µM for fusion enzymes f1 and f2 as well as for native GalE and alpha 1,3GalT.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Construction of pET15b-f1 and pET15b-f2-- The bifunctional enzyme f1 was prepared by in-frame linking of the galE gene downstream to the truncated alpha 1,3GalT gene, whose translational stop signal has been removed, through an in-frame linker (GGTGGAGGC) coding for three glycine residues. To obtain the plasmid pET15b-f1, the plasmids pET15b-alpha 1,3GalT (f1) encoding individual alpha 1,3GalT and pET15b-galE (f1) encoding GalE were constructed first (Fig. 2A). The gene for the alpha 1,3GalT was amplified with two primers alpha 1,3GalT-F-f1 (forward primer, containing restriction site NdeI) and alpha 1,3GalT-R-f1 (reverse primer, containing restriction sites SpeI, SalI, and BamHI and the codons of the three-glycine linker). NdeI and BamHI restriction sites facilitated the insertion of the alpha 1,3GalT gene into the multiple restriction sites in vector pET15b, while SpeI and SalI were for the introduction of the galE gene. Similarly, the galE gene was amplified by polymerase chain reaction from the chromosomal DNA of E. coli strain K-12 with primers galE-F-f1 (forward primer, containing NdeI and SpeI restriction sites) and galE-R-f1 (reverse primer, containing SalI and BamHI restriction sites). Plasmids pET15b-alpha 1,3GalT (f1) and pET15b-galE (f1) were obtained, respectively, by the digestion with NdeI and BamHI and consequent ligation with the pET15b vector. After confirmation by restriction mapping, both plasmids pET15b-alpha 1,3GalT (f1) and pET15b-galE (f1) were digested with SpeI and SalI. The 6.7-kb digested fragment of pET15b-alpha 1,3GalT (f1) and the 1.1-kb fragment of pET15b-galE (f1) were purified and ligated by T4 DNA ligase to form plasmid pET15b-f1.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Construction of the plasmids for fusion enzymes pET15b-f1 (A) and pET15b-f2 (B). The galE gene for UDP-Gal 4-epimerase was cloned directly from the genome of E. coli K-12 and constructed into pET15b vector. The gene of alpha 1,3-galactosyltransferase was amplified from a previously constructed plasmid and ligated into the same pET15b vector. A, pET15b-f1 was produced by the insertion of galE to the 3' terminus of the alpha 1,3-galactosyltransferase gene. B, pET15b-f2 was produced by the insertion of the alpha 1,3-galactosyltransferase gene into the 3'-terminus of the galE gene.

Another way of fusing the alpha 1,3GalT gene and galE gene together was to join the structural gene of alpha 1,3GalT to the 3'-end of the galE gene. In this case, the translational stop signal of the galE gene was removed. A similar strategy was applied to obtain plasmid pET15b-f2 for fusion protein f2 (Fig. 2B). The primers in the construction of fusion proteins are listed in Table I. All of the plasmids contained a T7 promoter, a T7 terminator, and an ampicillin-resistant gene. The His6 tag fused to the N terminus of the fusion proteins simplified the purification of enzymes by Ni2+-NTA affinity chromatography. The expressions of both f1 and f2 were under the control of the T7 lac promoter and induced by the addition of isopropyl-1-thio-beta -D-galactopyranoside.

                              
View this table:
[in this window]
[in a new window]
 
Table I
List of oligonucleotide primers used in the construction of plasmids pET15b-f1 and pET15b-f2 for the fusion proteins

The plasmid pET15b-f1 or pET15b-f2 was transformed into E. coli cloning host DH5alpha , and positive recombinants were transformed into E. coli expression host BL21 (DE3). Selected colonies were confirmed by restriction mapping and DNA sequencing. When pET15b-f1 was digested with NdeI and BamHI, two fragments with sizes of 5.7 kb (pET15b vector) and 2 kb (alpha 1,3GalT gene plus galE) were observed in agarose gel electrophoresis. When pET15b-f1 was digested with SpeI and SalI, two fragments with sizes of 6.6 kb (pET15b vector plus alpha 1,3GalT gene) and 1100 bp (galE) were observed (Fig. 3A). Similarly, when pET15b-f2 was digested with NdeI and BamHI, two fragments with sizes of 5.7 and 2 kb were shown. If f2 was digested with SalI and BamHI, two fragments with sizes of 6.8 and 900 bp (alpha 1,3GalT gene) were shown (Fig. 3B).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 3.   Restriction mapping of the plasmid for f1 (A) and f2 (B). Restriction mapping was performed in a 1% agarose gel in 1× TAE buffer (Tris acetate buffer containing 0.04 M Tris acetate and 0.001 M EDTA, pH 8.0) under 110-V direct current. Lanes 1, 6, 7, and 12, 1-kb DNA ladder (from top to bottom: 10 kb, 8 kb, 6 kb, 5 kb, 4 kb, 3.5 kb, 3 kb, 2.5 kb, 2 kb, 1.5 kb, 750 bp, 500 bp, and 250 bp); lane 2, pET15b-f1 digested by NdeI and BamHI; lane 3, pET15b-f1 digested by SpeI and SalI; lane 4, pET15b-galE (f1) digested by NdeI and BamHI; lane 5, pET15b-alpha 1,3GalT (f1) digested by NdeI and BamHI; lane 8, pET15b-f2 digested by NdeI and BamHI; lane 9, pET15b-f2 digested by SalI and BamHI; lane 10, pET15b-alpha 1,3GalT (f2) digested by NdeI and BamHI; lane 11, pET15b-galE (f2) digested with NdeI and BamHI.

Expression and Purification of Fusion Enzymes-- Both fusion proteins f1 and f2 were efficiently expressed in E. coli expression host BL21 (DE3) and appeared as predominant bands corresponding to a molecular mass of 67 kDa, which were absent in the BL21 (DE3) transformed with the pET15b vector plasmid only (Fig. 4). Under the expression conditions (37 °C, 250 rpm, 0.4 mM isopropyl-1-thio-beta -D-galactopyranoside induction for 3 h), about 12 units of f1 and 10 units of f2 were obtained from the cell lysate of 1 liter cell culture. A large percentage of the fusion proteins were expressed as inclusion bodies. The efficient extraction with 6 M guanidine HCl and proper refolding procedures retrieved 20 units of active enzymes from the inclusion bodies expressed in 1 liter of bacterial culture for both f1 and f2. Similarly to the refolding of recombinant beta 1,4-galactosyltransferase from the inclusion bodies overexpressed in the same E. coli pET15b-expressing system (25), the attempt at refolding using a buffer containing Tris-HCl (20 mM, pH 7.9), glycerol (10%), and dithiothreitol (1 mM) failed. The successful refolding was achieved in the same buffer except that the dithiothreitol was substituted by a redox system containing 10 mM 2-mercaptoethanol and 1 mM 2-hydroxyethyl disulfide. The necessity of a redox system for generating active enzymes indicated the importance of disulfide bond formation during refolding of the fusion proteins.


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 4.   SDS-PAGE of fusion enzymes f1 and f2. Performed in a 10% acrylamide at 200-V direct current, Coomassie Blue-stained. Lanes 1 and 5, high range molecular standard (from top to bottom: 212 kDa, 116 kDa, 97.4 kDa, 66.2 kDa, 57.5 kDa, and 40 kDa); lane 2, f1 purified by Ni2+-NTA affinity column and Superdex gel filtration FPLC chromatography; lane 3, f2 purified by Ni2+-NTA affinity column and Superdex gel filtration FPLC chromatography; lane 4, whole cell extract of BL21(DE3) transformed with pET15b vector plasmid.

A better expression level was achieved by lowering the temperature to 30 °C and elongating the incubation time to 20 h after the addition of isopropyl-1-thio-beta -D-galactopyranoside. However, as the case under the normal expression conditions (37 °C, 3 h), the amount of the proteins obtained from 1 liter of bacteria culture for f1 remained similar to that for f2, as determined by SDS-PAGE and the activity assay. These results indicated that the relative location of the transferase and the epimerase in the fusion enzymes was not critical for the expression level in the current overexpression system.

Purification of the fusion proteins was achieved by a nickel affinity chromatography and a subsequent FPLC HL Superdex 200 (16/60) gel filtration chromatography. After the affinity chromatography, the fusion proteins were purified to about 90% purity. Further purification was achieved for both f1 and f2 by FPLC gel filtration chromatography, which gave a single peak containing fusion protein activity in FPLC elution and a clean single band of about 67 kDa in SDS-PAGE (Fig. 4).

Molecular Mass Determination-- The molecular weights of the fusion enzymes were estimated by gel filtration chromatography on a Superdex 200 column. Both hybrid enzymes eluted as single peaks corresponding to a molecular mass of 140 kDa, as determined by comparison with the protein standards performed under the same conditions. The molecular mass for either f1 or f2 determined by SDS-PAGE was estimated to 67 kDa (Fig. 4). The monomers of both fusion proteins have theoretical calculated molecular masses of 74 kDa. These results suggest that both f1 and f2 are homodimers with total molecular mass of about 140 kDa under native conditions.

Apparent Kinetic Parameters for the Fusion Enzymes-- The measured kinetic parameters in Table II reveal some properties of the fusion enzymes. First, the kcat values of the alpha 1,3GalT moieties (UDP-Gal right-arrow Galalpha 1,3Lac reaction) in f1 and f2 are similar to that of the native alpha 1,3GalT. However, the Km value of f1 for lactose (8.5 mM) is decreased to about a half of that of the native alpha 1,3GalT (15 mM). Therefore, the catalytic efficiency of the alpha 1,3GalT moiety in f1 is higher (kcat/Km = 0.053 s-1 mM-1) compared with that of f2 or of the native alpha 1,3GalT. It is important to point out that the epimerase part of the fusion enzymes participated in the conversion of UDP-Gal to UDP-Glc, which decreased UDP-Gal concentration and slowed down the reaction, during the measurement of the alpha 1,3GalT activity for f1 and f2. Therefore, the kinetic parameters shown in Table II are only approximate determinations. Second, it is found that the catalytic efficiencies of the epimerase moieties (UDP-Glc right-arrow UDP-Gal reaction) in f1 and f2 are greatly reduced (~25-fold) in comparison with that of the native GalE. Dissecting to individual parameters, the kcat value of f1 is similar to that of the native GalE, and the efficiency loss of the GalE in f2 mainly comes from the poorer binding to UDP-Glc. For f2, the decrease of the efficiency comes from both a lower kcat and a higher Km. Third, when considering the overall fusion enzyme activity in the coupled reaction (UDP-Glc right-arrow Galalpha 1,3Lac reaction), the catalytic efficiency of f1 is about 8 times higher than that of f2. This is mainly due to the fact that f1 has a lower Km.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Apparent kinetic parameters of f1, f2, and related individual enzymes
All of the experiments were carried out in duplicate.

Proximity Effect-- UDP-Gal 4-epimerase catalyzes the interconversion of UDP-Glc to UDP-Gal (Reaction 1). alpha 1,3-galactosyltransferase catalyzes the addition of a galactose from UDP-Gal to its acceptor lactose (Reaction 2). The fusion enzymes contain both epimerase and transferase activities and will catalyze the transformation of galactose from UDP-Glc (instead of from UDP-Gal) to lactose (Reaction 3). The net result is the change of donor requirement of alpha 1,3GalT from UDP-Gal to UDP-Glc, which decreases the cost for the synthesis of alpha -Gal epitope and its derivatives more than 40-fold.


           <UP>UDP-Glc ⇔ UDP-Gal</UP>

<UNL><UP>UDP-Gal</UP>+<UP>lactose ⇔ &agr;-Gal epitope</UP>+<UP>UDP</UP></UNL>

<UP>UDP-Glc</UP>+<UP>lactose ⇔ &agr;-Gal epitope</UP>+<UP>UDP</UP>

<UP><SC>Reactions</SC> 1–3</UP>
Due to their proximity effects, the fusion proteins may also have kinetic advantages over the system containing two separate enzymes in terms of catalytic efficiency. To test this hypothesis, the rates of the coupled reaction catalyzed by the same amount of f1, f2, or a combination of the two native enzymes were measured and compared under same conditions (Fig. 5). Significantly, the initial rates of catalysis by the fusion enzyme f1 and f2 were about 300 and 50% higher, respectively, than those of the native enzymes at all substrate concentrations. The activity improvements of the fusion enzymes suggested that proximity effects occurred in the fusion enzymes to increase the catalytic activities for the overall reaction. UDP-Gal produced by the epimerase should have traveled a shorter distance to be captured by the alpha 1,3-galactosyltransferase active sites in the fusion proteins compared with that of the two-enzyme system.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Initial rates for the formation of Galalpha 1,3Lac catalyzed by f1, f2, or a mixture of alpha 1,3-galactosyltransferase and the epimerase at various concentrations of lactose and fixed concentration of UDP-Glc (0.3 mM). The same concentration (0.3 µM) of f1, f2, or the mixture of alpha 1,3GalT and GalE was used under the same reaction conditions (30 min in a 37 °C water bath). black-square, f1; black-diamond , f2; , mixed native epimerase and transferase.

Acceptor Specificity-- The natural acceptor for native alpha 1,3-galactosyltransferase is N-acetyllactosamine. The recombinant alpha 1,3-galactosyltransferase was shown to be able to accept a wide range of substrates including lactose and galactose derivatives but not glucose derivatives (29). In order to determine whether the acceptor specificity of the alpha 1,3-galactosyltransferase had been changed after the fusion with epimerase, acceptor specificities were measured for fusion protein f2. Selected monosaccharides and disaccharides were used as the acceptors, and either UDP-Gal or UDP-Glc was used as the sugar nucleotide donor for the alpha 1,3GalT activity and the overall coupled reaction.

As shown in Table III, the acceptor specificity of the alpha 1,3-galactosyltransferase moiety (UDP-Gal right-arrow Galalpha 1,3Lac reaction) in f2 and that of the overall fusion enzyme f2 (UDP-Glc right-arrow Galalpha 1,3Lac reaction) are similar to that obtained for the individual recombinant alpha 1,3-galactosyltransferase. For example, lactose derivatives are acceptors for the hybrid protein f2 and the alpha 1,3-galactosyltransferase moiety in f2 with the activities corresponding to the substitution of aglycones as N3 > OH > SPh. The presence of axial configuration of hydroxyl group at the C-4 position of the Gal residue is important. Lactose and galactose derivatives are acceptors; however, glucose derivatives are not accepted by the enzyme. As in the case of the recombinant alpha 1,3GalT, alpha - or beta -linkage of the Gal terminus at the nonreducing end was confirmed to be an important but not crucial factor for f2. All of the Gal beta -linked compounds (entries 1-4, 6, 7) are much better acceptors than the Gal alpha -linked compounds (entries 5, 8).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Acceptor specificity of f2
The assays are carried out in duplicate at 37 °C for 30 min with UDP-Gal (0.3 mM) or UDP-Glc (0.3 mM) and fixed acceptor concentration (50 mM) in the presence of 10 mM MnCl2 in a total volume of 0.1 ml.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Full-length bovine alpha 1,3-galactosyltransferase is a type II membrane protein with a short N-terminal cytosolic domain, a transmembrane domain, a stem region, and a C-terminal catalytic domain (30). The native alpha 1,3-galactosyltransferase is a monomer with a molecular mass of 43 kDa (31). We reported previously a high yield expression of a truncated (the first 79 N-terminal amino acid residues were deleted) recombinant bovine alpha 1,3-galactosyltransferase (19). FPLC gel filtration analysis and SDS-polyacrylamide gel electrophoresis data indicate that the recombinant alpha 1,3-galactosyltransferase is a monomer.

UDP-Gal 4-epimerase is one of the key enzymes of the Leloir pathway for galactose metabolism (32). The epimerase from E. coli is a homodimer with an overall molecular mass of 79 kDa (33). The epimerase was cloned from E. coli K-12 into pET15b expression vector (27). FPLC gel filtration and SDS-PAGE data indicate that the recombinant epimerase is a homodimer. It is interesting to know that both fusion proteins f1 and f2 have dimeric configurations as that for the native epimerase. The relative position of the transferase and the epimerase does not alter this property. Also, the His6 tag at the N terminus of protein does not prevent dimerization. Since the recombinant alpha 1,3GalT is a monomer, the recombinant epimerase is a homodimer, it is reasonable to assume that, the interactions between the two subunits of the fusion proteins result from the interactions of the epimerase moieties in the fusion enzymes (Fig. 6). The same conclusion was made by Bulow and Mosbach (34) that a dimeric hybrid polypeptide alpha -beta beta -alpha was usually obtained by the fusion of a dimeric protein (beta beta ) with a monomeric one (alpha ).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Schematic representations of f1 (A) and f2 (B) homodimer. Single-letter amino acid codes are used.

A previous report about a fusion protein composed of UDP-Gal 4-epimerase and galactose-1-phosphate uridylyltransferase (GalT) with an intervening Ala3 linker was shown to exist in three forms: a monomer, dimer, or tetramer (20). Another fusion protein of beta -galactosidase and galactose dehydrogenase was also shown to exist as two major forms, consisting of four or six subunits, as well as other forms (21). Unlike these reports, due to the monomeric nature of the alpha 1,3GalT, both fusion proteins f1 and f2 in the present study exist as homodimers.

It was reported that each subunit of the dimeric epimerase contained one irreversibly, noncovalently bound NAD+ (33), and no additional NAD+ was required for the epimerase-catalyzed reaction (32). This is also the case for the fusion enzymes. No external NAD+ is necessary for either the coupled reaction or the activity of the epimerase moiety in the fusion enzymes. This indicates that NAD+ is also tightly bound to the epimerase during the expression of fusion proteins in E. coli.

Our kinetic studies indicate that the fusion proteins have kinetic advantages over the system of individual enzymes for the overall coupled reaction. Significantly, the reaction rates in producing Galalpha 1,3Lac from UDP-Glc and lactose are increased 4- and 1.5-fold by f1 and f2, respectively, in comparison with the native enzymes. This result can be explained by the substrate channeling effect (21), indicating that the UDP-Gal produced by the epimerase is captured faster by the transferase moiety in either f1 or f2 than that in the system of native enzymes. Furthermore, the higher activity of f1 over f2 suggests that the active sites for the epimerase and alpha 1,3-galactosyltransferase part are in a more optimal configuration in f1.

It is noticed that the overall fusion enzyme activities (UDP-Glc right-arrow Galalpha 1,3Lac reaction) are higher than the activity of the corresponding transferase moieties (UDP-Gal right-arrow Galalpha 1,3Lac reaction) in both f1 and f2. This provided us with an insight into the mechanism of alpha 1,3-galactosyltransferase. The steady state kinetic properties of alpha 1,3-galactosyltransferase indicate a sequential mechanism in which metal cofactor, donor, and acceptor bind enzyme prior to catalysis. The low level of UDP-Gal hydrolase activity found in alpha 1,3-galactosyltransferase excluded the possibility of an ordered sequential mechanism with binding of acceptor prior to donor. Previous studies were not able to determine whether an ordered mechanism with the binding of donor prior to acceptor or a random mechanism applies for alpha 1,3-galactosyltransferase. Our results on the kinetic parameters of coupled reaction and the native transferase reaction in both fusion enzymes suggest that a random mechanism should be a more plausible explanation. For instance, if alpha 1,3-galactosyltransferase obeys an ordered mechanism with the binding of donor prior to acceptor, then in the absence of UDP-Gal (as in the coupled reaction), UDP-Glc has to be captured by the epimerase and be converted to UDP-Gal prior to the function of transferase. Opposite to the results we obtained, the initial rate in the coupled reaction should be lower than that in the activity assay for the alpha 1,3-galactosyltransferase moieties in fusion enzymes, in which UDP-Gal is present and able to be captured and utilized by the transferase right away.

Beside N-acetyllactosamine, lactose and lactose derivatives are found to be good acceptors for the recombinant alpha 1,3-galactosyltransferase. Our results indicate that the in-frame fusing with epimerase does not change the acceptor specificity of the transferase. This suggests that without changing many important properties of individual native enzymes, fusing two enzymes together has the advantages of simplicity, economy, and efficiency. In our laboratory, the fusion enzymes f1 and f2 have been successfully applied in the synthesis of alpha -Gal epitope and its derivatives (35, 36). This novel approach reduces the cost for the synthesis of oligosaccharide by over 40-fold and provides an easy and economic access to a wide spectrum of alpha -galactosyl epitopes and their derivatives to support the continuous studies on xenotransplantation as well as other pharmaceutical research (37, 38). The methodology can also be applied for other galactosyltransferases that require UDP-Gal as the donor, such as alpha 1,4-galactosyltransferase, alpha 1,6-galactosyltransferase, beta 1,4-galactosyltransferase, beta 1,3-galactosyltransferase, human blood type B galactosyltransferase, etc. From a broader point of view, depending on which sugar nucleotide is the most economical source, the fusion of a glycosyltransferase and an epimerase can change a required, but more expensive, sugar nucleotide to a less expensive one. For instance, broader application of such an approach may include the combination of a variety of glycosyltransferases with different epimerases, such as N-acetylgalactosaminyltransferase and UDP-N-acetylglucosamine 4-epimerase, galactosaminyltransferase and UDP-N-glucosamine 4-epimerase, or galacturonosyltransferase and UDP-glucuronate 4-epimerase.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant AI44040.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 313-993-6759; Fax: 313-577-2554; E-mail: pwang@chem.wayne.edu.

Published, JBC Papers in Press, July 25, 2000, DOI 10.1074/jbc.M004005200

    ABBREVIATIONS

The abbreviations used are: alpha -Gal, Galalpha 1,3Galbeta -R-terminated oligosaccharide, glycopeptide, or glycolipid; alpha -Gal trisaccharide, Galalpha 1,3Galbeta 1,4GlcOH; alpha 1, 3GalT, alpha 1,3-galactosyltransferase; GalE, uridine diphosphogalactose 4-epimerase; PAGE, polyacrylamide gel electrophoresis; NTA, nitrilotriacetic acid; bp, base pairs; kb, kilobase pair(s); FPLC, fast protein liquid chromatography.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Miller, D. J., Macek, M. B., and Shur, B. D. (1992) Nature 357, 589-593
2. Bayna, E. M., Shaper, J. H., and Shur, B. D. (1988) Cell 53, 145-157
3. Parker, W., Saadi, S., Lin, S. S., Holzknecht, Z. E., Bustos, M., and Platt, J. L. (1996) Immunol. Today 17, 373-378
4. Good, A. H., Cooper, D. K. C., Malcolm, A. J., Ippolito, R. M., Koren, E., Neethling, F. A., Ye, Y., Zuhidi, N., and Lamontagne, L. R. (1992) Transplant. Proc. 24, 559-562
5. Sandrin, M. S., Vaughan, H. A., Dabkowski, P. L., and McKenzie, I. F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11391-11395
6. Galili, U., and Swanson, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7401-7404
7. Joziasse, D. H., Shaper, J. H., Van den Eijnden, D. H., Van Tunen, A. J., and Shaper, N. L. (1989) J. Biol. Chem. 264, 14290-14297
8. Galili, U., Anaraki, F., Thall, A., Hill-Blank, C., and Radic, M. (1993) Blood 82, 2485-2493
9. Chen, X., Andreana, P., and Wang, P. G. (1999) Curr. Opin. Chem. Biol. 3, 650-658
10. Simon, P., Neethling, F. A., Taniguchi, S., Good, P. L., Zopf, D., Hancock, W. W., and Cooper, D. K. C. (1998) Transplantation 65, 346-353
11. Koike, K., Sugimoto, M., Sato, S., Ito, Y., Nakahara, Y., and Ogawa, T. (1987) Carbohydr. Res. 163, 189-208
12. Matsuzaki, Y., Ito, Y., Nakahara, Y., and Ogawa, T. (1993) Tetrahedron Lett. 34, 1061-1064
13. Reddy, G. V., Jain, R. K., Bhatti, B. S., and Matta, K. L. (1994) Carbohydr. Res. 263, 67-77
14. Beyer, A. T., Sadler, J. E., Rearick, J. I., Paulson, J. C., and Hill, R. L. (1981) Adv. Enzymol. 52, 24-175
15. Wong, C.-H., Haynie, S. L., and Whitesides, G. M. (1982) J. Org. Chem. 47, 5416-5418
16. Wong, C.-H., Wang, R., and Ichikawa, Y. (1992) J. Org. Chem. 57, 4343-4344
17. Auge, C., Mathieu, C., and Merienne, C. (1986) Carbohydr. Res. 151, 147-156
18. Thiem, J., and Wiemann, T. (1992) Synthesis (Stuttgart) 1-2, 141-145
19. Fang, J. W., Li, J., Chen, X., Zhang, Y. N., Wang, J. Q., Guo, Z. M., Zhang, W., Yu, L. B., Brew, K., and Wang, P. G. (1998) J. Am. Chem. Soc. 120, 6635-6638
20. Tamada, Y., Swanson, B. A., Arabshahi, A., and Frey, P. A. (1994) Bioconjugate Chem. 5, 660-665
21. Ljungcranyz, P., Carlsson, H., Mansson, M. O., Buckel, P., Mosbach, K., and Bulow, L. (1989) Biochemistry 28, 8786-8792
22. Saxena, I. D., brown, R. M., Fevre, M., Geremia, R. A., and Henrissat, B. (1995) J. Bacteriol. 177, 1419-1424
23. Lougheed, B., Ly, H. D., Wakarchuk, W. W., and Withers, S. G. (1999) J. Biol. Chem. 274, 37717-37722
24. Kapitonow, D., and Yu, R. K. (1999) Glycobiology 9, 961-978
25. Zhang, Y. N., Malinovskii, V. A., Fiedler, T. J., and Brew, K. (1999) Glycobiology 9, 815-822
26. Mach, H., Middaugh, C. R., and Lewis, R. V. (1992) Anal. Biochem. 200, 74-80
27. Chen, X., Kowal, P., Hamad, S., Fan, H. N., and Wang, P. G. (1999) Biotech. Lett. 21, 1131-1135
28. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275
29. Chen, X., Zhang, W., Wang, J. Q., Fang, J. W., and Wang, P. G. (2000) Biotech. Prog. 16, 595-599
30. Blanken, W. M., and Van den Eijnden, D. H. (1985) J. Biol. Chem. 260, 12927-12934
31. Wilson, D. B., and Hogness, D. S. (1964) J. Biol. Chem. 239, 2469-2481
32. Burke, J. R., and Frey, P. A. (1993) Biochemistry 32, 13220-13230
33. Thoden, J. B., Frey, P. A., and Holden, H. M. (1996) Biochemistry 35, 5137-5144
34. Bulow, L., and Mosbach, K. (1991) Trends Biotechnol. 9, 226-231
35. Fang, J. W., Chen, X., Zhang, W., Wang, J., Andreana, P. R., and Wang, P. G. (1999) J. Org. Chem. 64, 4089-4094
36. Wang, J. Q., Chen, X., Zhang, W., Zacharek, S., Chen, Y. S., and Wang, P. G. (1999) J. Am. Chem. Soc. 121, 8174-8181
37. Zhang, W., Xie, W. H., Wang, J. Q., Chen, X., Fang, J. W., Chen, Y. S., Li, J., Yu, L. B., Chen, D. P., and Wang, P. G. (1999) Curr. Org. Chem. 3, 241-267
38. Janczuk, A., Li, J., Zhang, W., Chen, X., Chen, Y. S., Fang, J. W., Wang, J. Q., and Wang, P. G. (1999) Curr. Med. Chem. 6, 155-164


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
GlycobiologyHome page
P. Bobrowicz, R. C. Davidson, H. Li, T. I. Potgieter, J. H. Nett, S. R. Hamilton, T. A. Stadheim, R. G. Miele, B. Bobrowicz, T. Mitchell, et al.
Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose
Glycobiology, September 1, 2004; 14(9): 757 - 766.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
Z. Liu, Y. Lu, J. Zhang, K. Pardee, and P. G. Wang
P1 Trisaccharide (Gal{alpha}1,4Gal{beta}1,4GlcNAc) Synthesis by Enzyme Glycosylation Reactions Using Recombinant Escherichia coli
Appl. Envir. Microbiol., April 1, 2003; 69(4): 2110 - 2115.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Li, T.-Y. Yen, M. L. Allende, R. K. Joshi, J. Cai, W. M. Pierce, E. Jaskiewicz, D. S. Darling, B. A. Macher, and W. W. Young Jr.
Disulfide Bonds of GM2 Synthase Homodimers. ANTIPARALLEL ORIENTATION OF THE CATALYTIC DOMAINS
J. Biol. Chem., December 22, 2000; 275(52): 41476 - 41486.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/41/31594    most recent
M004005200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by